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Abstract  
Findings on the association between alcohol consumption and bladder cancer are inconsistent. 
We investigated that association in the European Prospective Investigation into Cancer and 
Nutrition cohort. We included 476,160 individuals mostly aged 35-70 years, enrolled in ten 
countries and followed for 13.9 years on average. Hazard ratios (HR) for developing 
urothelial cell carcinoma (UCC; 1,802 incident cases) were calculated using Cox proportional 
hazards models. Alcohol consumption at baseline and over the life course was analyzed, as 
well as different types of beverages (beer, wine, spirits). Baseline alcohol intake was 
associated with a statistically non-significant increased risk of UCC (HR 1.03; 95% 
confidence interval (CI) 1.00-1.06 for each additional 12 grams/day). HR in smokers was 1.04 
(95% CI 1.01-1.07). Men reporting high baseline intakes of alcohol (>96 grams/day) had an 
increased risk of UCC (HR 1.57; 95% CI 1.03-2.40) compared to those reporting moderate 
intakes (<6 grams/day), but no dose-response relationship emerged. In men, an increased risk 
of aggressive forms of UCC was observed even at lower doses (>6 to 24 grams/day). Average 
lifelong alcohol intake was not associated with the risk of UCC, however intakes of spirits > 
24 grams/day were associated with an increased risk of UCC in men (1.38; 95% CI 1.01-1.91) 
and smokers (1.39; 95% CI 1.01-1.92), compared to moderate intakes. We found no 
association between alcohol and UCC in women and never smokers. In conclusion, we 
observed some associations between alcohol and UCC in men and in smokers, possibly due to 
residual confounding by tobacco smoking. 
 
Novelty and Impact  
Findings from the EPIC cohort do not suggest a clear detrimental effect of alcohol on 
bladder cancer risk. However, we found some association between alcohol and risk of the 
most aggressive forms of bladder cancer in men and in smokers. Among the different 
beverages, high intakes of spirits were associated with an increased risk of bladder cancer in 




An estimated 429,000 bladder cancer cases occurred worldwide in 2012, making it the 
ninth most common cause of cancer for both sexes combined. The disease is more common in 
more developed than less developed regions and in men than women (sex ratio of 3.5:1) [1]. 
In addition to gender, established risk factors include race [2], cigarette smoking [3], 
occupational exposure to aromatic amines and polycyclic aromatic hydrocarbons [4], arsenic 
in drinking water [5] and Schistosoma haematobium infection [6]. Whether alcohol 
consumption is a risk factor for bladder cancer remains controversial. A review of six cohort 
studies and 21 case-control studies published by the International Agency for Research on 
Cancer (IARC) showed that the evidence for an association between alcohol and bladder 
cancer is inconclusive [7]. A meta-analysis published in 2012, combining the evidence from 3 
cohort and 16 case-control studies, showed no association between alcohol consumption and 
bladder cancer risk [8]. A second meta-analysis published in 2015, based on the same 19 
studies, examined the dose-response relation between bladder cancer risk and alcohol 
drinking [9], and showed no evidence of such a relation. However, results from the included 
studies differed, and consequently a significant heterogeneity among the pooled estimates was 
reported in both meta-analyses. 
We investigated the association between alcohol consumption and the risk of 
urothelial cell carcinoma (UCC), the main morphological type of urinary bladder cancer, in 
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. With 
476,160 individuals and 1,802 incident UCC cases, this large cohort study aims at providing 
novel insights into the relation between alcohol consumption and UCC risk. Alcohol 
consumption at baseline and over the life course is analyzed, as well as different types of 
alcoholic beverages (i.e. beer, wine, spirits). Also, we distinguish non-aggressive from 
aggressive UCCs. All analyses are presented by gender and smoking status. 
Materials and Methods 
Study participants 
Design and methods of the EPIC cohort, including detailed description of the 
questionnaires used to collect data on lifestyle, health and sociodemographic characteristics, 
have been described previously [10,11]. Briefly, the cohort includes 23 centers in ten 
countries: Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden 
and United Kingdom. Participants were mostly 30–75 years at baseline (1991–2000), and 
were mostly recruited from the general population. 521,457 participants were included, and 
gave written, informed consent to the use of their data for research purposes. Information on 
socio-demographic characteristics, anthropometric measures, physical activity, medical 
history and alcohol and tobacco consumption was assessed at recruitment using validated 
country-specific or center-specific lifestyle questionnaires designed to capture habitual 
consumption over the preceding year. Energy (kcal/day) was estimated using the EPIC 
Nutrient Database [12]. Height and weight were measured in most of the centres, except for 
Oxford (UK), France and Norway where they were self-reported. Body mass index (BMI) 
was calculated as weight in kilograms divided by squared height in metres (kg/m2). 
From the whole EPIC cohort of 521,324 subjects, we excluded 25,184 subjects with 
prevalent cancer (any cancer except nonmelanoma skin cancer), 4,148 without follow-up data 
and 15,832 subjects without information on alcohol consumption. A total of 476,160 subjects 
were included in the present study.  
Cancer ascertainment was mostly based on population cancer registries, except for 
France, Germany, Italy (Naples center) and Greece, where a combination of methods 
including health insurance records, cancer and pathology hospital registries, and active 
follow-up were used. Mortality data were collected from registries at the regional or national 
level. Subjects were followed up from study entry and until cancer diagnosis (except non-
melanoma skin cancer), death, emigration or until the end of the follow-up period, whichever 
occurred first. Overall, 1,237 (0.26%) were lost to follow-up. The date of the last complete 
follow-up ranged from June 2008 to December 2013, depending on the center. 
 
Exposure assessment 
Participants reported on how many standard glasses of beer, wine, sweet liquor, 
distilled spirits, and fortified wine they had consumed per day or per week during the 12 
months prior to recruitment. Lifetime alcohol consumption was assessed based on self-
reported weekly consumption of those alcoholic beverages at ages 20, 30, 40, and 50 years in 
the lifestyle questionnaire. The average lifetime daily consumption was calculated and used in 
the analyses. The duration of alcohol consumption was calculated by the difference between 
the age when an individual started to drink alcohol and the age of last reported consumption 
(the latter was the same as the age at recruitment for current drinkers). Information on lifetime 
alcohol consumption was available for 76% of the individuals with baseline alcohol 
consumption. For the present analysis, liquor, spirits, and fortified wine were combined in a 
single category (i.e. 'spirits') because of their common high concentration of alcohol per 
volume of drink. We used alcohol from alcoholic beverages as exposure, both as a continuous 
and a categorical variable. When used as continuous, the unit of increment was one standard 
drink a day, corresponding to 12 grams of alcohol a day (g/d). When used in categories, a 
gender-specific reference group was implemented: >0–6 g/d for males (M) and >0–3 g/d for 
females (F). The remaining categories were: non-drinker, >6-12(M)/>3-12(F) g/d, >12-24 g/d, 




The primary endpoint was the first occurrence of primary UCC (topography code 67 
and morphology codes 812-813 according to the ICD-Oncology, third edition). Other bladder 
cancer types and cases with behaviors coded as ‘benign’ and ‘uncertain whether benign or 
malignant’ were censored at time of diagnosis, while cases with behaviors coded as 
‘carcinomas in situ’ or ‘malignant’ were included as cases. UCCs were further classified as 
non-aggressive (pTa, Grade 1 and 2) and aggressive (pT1 and higher or CIS or Grade 3, 
including pTa, Grade 3). In a sensitivity analysis, we also tested an alternative stratification in 
less advanced (pTa/CIS/pT1) and more advanced UCCs (pT2 and higher). 
 
Statistical methods 
Multivariable Cox proportional hazards regression models were used to assess the 
impact of alcohol intake on UCC risk. Hazard ratios (HRs) and confidence intervals (CIs) 
were estimated using age as the underlying time scale, with entry time defined as the 
participant’s age at baseline and exit time as age at UCC diagnosis or censoring (diagnosis of 
any cancer, except nonmelanoma skin cancer; death; emigration; loss to follow-up; or end of 
follow-up, whichever came first). All models were stratified by age at recruitment (1-year 
intervals), gender and study center and adjusted for smoking status (current, 1-15 
cigarettes/day; current, 16-25 cigarettes/day; current, 26+ cig/day; current, 
pipe/cigar/occasional cigarettes smoker; current/former, missing; former, quit 11-20 years; 
former, quit 20+ years; former, quit <= 10 years; never; missing), energy intake (kcal/day; 
continuous), BMI (continuous), physical activity (active; moderately active; moderately 
inactive; inactive; missing) and educational level completed (primary school; secondary 
school; university degree or higher; technical/professional school; none; missing). Adjustment 
for smoking status was kept in the models even when we limited the analysis to smokers only 
(current and former). 
The following sub-analyses were conducted: association between alcohol and UCC 
risk by sex, smoking status (never; ever (former and current)) and by age (5-year intervals). In 
a sensitivity analysis we excluded UCC cases diagnosed within the first 2 years of follow-up 
to control for potential changes in alcohol consumption due to early symptoms of UCC. In a 
second sensitivity analysis, we limited the analysis to the study-centers in which information 
on occupational exposure was available, and we additionally adjusted the alcohol estimates 
for occupational exposure to aromatic amines (e.g. workers in dye production, textile and 
leather dying, and hairdressers) and polycyclic aromatic hydrocarbons (e.g. workers in the 
transport and asphalt sector, car repair stations, and refineries) [4]. 
All statistical tests were two-sided, and P-values < 0.05 were considered statistically 




A total of 476,160 participants (70.1% females) were followed for a mean of 13.9 
years, during which 1,802 UCC cases (1,273 male, 529 female) were diagnosed: 871 
aggressive, 384 non-aggressive and 547 unclassified cases (Table 1). Mean age at recruitment 
was 51.2 years. Baseline characteristics according to different levels of alcohol consumption 
are shown in Table 2. The educational level attained and the proportion of smokers, the 
proportion of moderately active and active, as well as energy intake, steadily increased with 
increasing levels of alcohol consumption in both sexes.  
In Table 3 we reported the estimates of the association between alcohol consumption, 
analyzed as a continuous variable, and the risk of UCC. The HR for baseline alcohol intake 
was 1.03 (95% CI 1.00-1.06) for each additional 12 g/d. The risk estimates in ever and never 
smokers were 1.04 (95% CI 1.01-1.07) and 0.93 (0.84-1.03), respectively. We stratified the 
population by age at baseline using the following categories: <50 years (UCC cases/number at 
risk: 272/201,914), 50-54 (334/104,515), 55-59 (447/76,863), 60-64 (499/61,000) and ≥65 
(250/31,868) and the corresponding UCC risk estimates for each additional 12 g/d were 0.99 
(95% 0.92-1.06), 1.06 (1.00-1.13), 1.05 (1.00-1.11), 1.01 (0.95-1.07), 0.98 (0.88-1.10). 
Average lifetime consumption was not statistically significantly associated with bladder 
cancer. In addition, no significant association was observed between baseline and lifetime 
consumption of beer, wine and spirits and risk of UCC. 
In Table 4 we reported the estimates of the association between alcohol consumption, 
analyzed as a categorical variable, and the risk of UCC. No clear dose-response relationship 
between baseline alcohol intake and UCC risk emerged. However, men who reported high 
intakes of alcohol (>96 g/d) had an increased risk of UCC (HR 1.57; 95% CI 1.03-2.40) 
compared to those who reported moderate intakes (>0-6 g/d). A similar pattern was observed 
in smokers. Notably, all 26 UCC cases in the high intake category were male smokers. There 
was no significant association between average lifetime consumption and bladder cancer.  
No significant association was observed between baseline consumption of beer, wine 
and spirits and risk of UCC (Supplementary Table 1). However average lifetime intakes of 
spirits > 24 g/d were associated with an increased risk of UCC in men (1.38; 95% CI 1.01-
1.91) and smokers (1.39; 95% CI 1.01-1.92), as compared to moderate intakes 
(Supplementary Table 2). 
Baseline and average lifetime alcohol intakes, analyzed as continuous variables, were 
not associated with an increased risk of aggressive UCC (Supplementary Table 3). No clear 
dose-response relationship emerged when alcohol consumption was analyzed as a categorical 
variable (Supplementary Table 4). Men who reported a baseline consumption of more than 6 
to 24 g/d and >96 g/d had a significantly increased risk of aggressive UCC compared to men 
who reported moderate intakes (>0-6 g/d). However, men who reported more than 24 to 96 
g/d had no significant increased risk of aggressive UCC. A similar non-monotonous trend was 
observed in smokers. No significant association between alcohol consumption and risk of 
non-aggressive UCC was observed (data not shown). No significant association between 
alcohol consumption and risk of non-aggressive UCC was observed. When we used the 
classification based on tumor growth only, we found no association of alcohol consumption 
with either less advanced UCCs (pTa/CIS/pT1; n=911) or more advanced UCCs (pT2 and 
higher; n=287) (data not shown). We found no significant association between the duration of 
alcohol consumption and the risk of UCC (data not shown). 
In Supplementary Table 5 we reported a complete multivariable model to show the 
association of gender, education, smoking status, physical activity, BMI and energy intake 
with the risk of UCC. Gender and smoking status were significantly associated with the risk 
of UCC. 
When we excluded the 124 UCC cases diagnosed within the first 2 years of 
observation, results remained essentially unchanged. Moreover, no significant variation was 
observed when we limited the analysis to the study-centers in which information on 
occupational exposure was available and we further adjusted for occupational exposure to 




The results from this large cohort study across ten Western European countries do not 
suggest a clear association between alcohol consumption and the risk of UCC. Some evidence 
of a possible positive association between high intakes of alcohol and the risk of UCC was 
restricted to men and smokers. Also, a possible association between alcohol and the risk of 
aggressive UCC was also found in men and in smokers. However, no clear dose-response 
relationship between alcohol intake and UCC risk and no significant association in never 
smokers emerged.  
The mechanisms by which alcohol consumption may exert its carcinogenic effect are 
not fully understood. Acetaldehyde, the first metabolite of ethanol, accounts for a 
considerable part, if not most, of the carcinogenicity of alcohol drinking [7,13]. Acetaldehyde 
is excreted through the urinary tract and is present in the urine after drinking of alcohol 
[14,15], and therefore a mechanistic role of alcohol consumption in the occurrence of UCC is 
plausible. Such a causal relationship is also supported by that polymorphisms in genes 
encoding the alcohol-metabolizing enzymes aldehyde dehydrogenase 2 and alcohol 
dehydrogenase 1B affect bladder cancer risk in a recent small case-control study [16]. On the 
other hand, alcoholic beverages might protect against UCC, as increased fluid intake dilute 
the carcinogens in the urine and increase the frequency of voiding, reducing contact of 
carcinogens with the bladder epithelium [17]. A large amount of epidemiological data on the 
association between alcohol and bladder cancer is available. In a monograph dedicated to 
personal habits and cancer risk, IARC reported a review of six cohort studies and 21 case-
control studies on alcohol drinking and UCC risk, and concluded that the evidence for an 
association is inconclusive [7]. Two meta-analyses, published in 2012 and 2015, combining 
the evidence from 3 cohort and 16 case-control studies, showed no overall association and no 
dose-response trend between alcohol consumption and bladder cancer risk [8,9]. The World 
Research Fund International Continuous Update Project classified the evidence of the 
association between alcohol and bladder cancer as limited and inconclusive [18]. 
In agreement with the existing literature, the results of our study do not suggest a clear 
association between alcohol consumption and bladder cancer risk. We found that the average 
intake of alcohol over the life course was not associated with an increased risk of UCC. 
Baseline alcohol intake analyzed as a continuous variable was associated with a significant 
increased risk of UCC only in smokers (4% increase for each additional drink), and high 
baseline intakes of alcohol (>96 g/d) increased the risk of UCC only in men and in smokers. 
The presence of an association in smokers might suggest a synergistic or exacerbating effect 
of acetaldehyde (or derived products) in conjunction with soluble tobacco carcinogens in 
contact with the bladder epithelium.  We found no clear dose-response relation between 
alcohol and UCC risk, and no evidence of an association in women and in never smokers. 
Altogether, these results suggest that if an increased risk of UCC exists, it is probably weak 
and mainly confined to the higher consumption categories. However, some new evidence of 
an association between alcohol consumption and the risk of the most aggressive forms of 
UCC was found in men and in smokers. These results might suggest a possible role of alcohol 
in facilitating tumor progression, or suggest that alcohol selectively increases the risk of fast 
growing forms of UCC. To our knowledge, no other papers reported on the association 
between alcohol and subtypes of UCC, therefore further studies are needed to clarify this 
issue.  
The role of residual confounding by smoking cannot be ruled out in our study. 
Tobacco smoking is the leading cause of UCC, with a population attributable risk of 50% in 
both sexes [19], and it is positively correlated with alcohol drinking. Therefore smoking can 
act as a powerful confounder in the link between alcohol and UCC. In the meta-analysis by 
Pelucchi et al. [8] the excess risk of bladder cancer due to high consumption of alcohol 
vanished when the smoking-unadjusted estimates were removed from the analysis. Similarly, 
in our study, the smoking-adjusted and smoking-unadjusted UCC risk estimates were 1.07 
(95% CI 1.04-1.10) and 1.03 (95% CI 1.00-1.06), respectively, for each additional drink per 
day reported at baseline. 
With regard to the different types of alcoholic beverages, we found that an average 
lifetime consumption of more than 2 glasses of spirits a day increased the risk of UCC in men 
and in smokers, while no significant association with beer and wine was found. The higher 
concentration of alcohol per drink volume in spirits compared to beer and wine might explain 
these results. However, residual confounding by smoking might again be accountable for the 
observation, as no dose-response relationship between spirits and UCC risk was observed and 
no association was observed in never smokers. In contrast to our findings, a 2010 meta-
analysis reported a negative association of beer and wine with bladder cancer and no 
association of spirits [20]. The authors hypothesized that certain phenolic compounds, namely 
Xanthohumol in beer and Resveratrol in wine, might be responsible for the possible protective 
effect [21,22]. However, the meta-analysis was based on a small number of investigations and 
significant heterogeneity was reported between studies reporting on beer and wine 
consumption. Also, none of the studies included in the meta-analysis showed a significant 
association in non-smokers.  
The strengths of this study include its prospective design, long follow-up and multi-
center European design. We could analyze alcohol consumption at baseline and over the life 
course, as well as different types of alcoholic beverages. In addition, we were able to select 
UCC tumors only, to limit possible differential effects of alcohol on other rare bladder cancer 
types. The main novelty our paper is given by the possibility to analyze a subset of UCC 
tumors according to their stage. Since tobacco smoking is the most important bladder cancer 
risk factor we carefully adjusted for its potentially confounding effect by including smoking 
status, intensity and time since quitting in all statistical models, and by presenting results 
stratified by smoking status. However, residual confounding by tobacco smoking could still 
be present. This is an important limitation, together with the potential measurement errors 
from dietary questionnaires, which potentially led to recall, response and misclassification 
bias for the alcohol exposure assessment. Also, information on race was missing; however 
participants were mostly Caucasians. Another limitation is given by the lack of information 
on the changes in the covariates, especially smoking, during the long follow-up of the study. 
In addition, despite the large cohort size, we found a relatively small number of UCC cases in 
certain subgroups of subjects (e.g. non-smokers) therefore the power for testing the 
association between alcohol and UCC risk in those subgroups was limited. 
In conclusion, our findings do not suggest a clear detrimental effect of alcohol 
consumption on bladder cancer risk. Residual confounding by smoking might explain the 
association between high intakes of alcohol and the increase in UCC risk observed in men and 
in smokers. However, new studies investigating the association between alcohol consumption 
and the most aggressive forms of UCC are warranted. 
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Denmark 55,014 (47.8) 815,097 355 326 273 11 
France 67,403 (0.0) 869,372 43 40 18 22 
Germany 48,557 (43.6) 504,479 169 150 82 53 
Greece 26,048 (41.5) 281,284 57 35 14 5 
Italy 44,545 (31.5) 630,920 231 209 86 67 
Norway 33,975 (0.0) 452,171 21 20 2 7 
Spain 39,989 (37.9) 637,947 234 219 147 32 
Sweden 48,674 (45.8) 801,130 413 399 113 86 
The Netherlands 36,539 (26.3) 524,671 167 160 73 84 
UK 75,416 (30.3) 1,122,765 282 244 63 17 
Total 476,160 (29.9) 6,639,836 1,972 1,802 871 384 
 
EPIC: European prospective investigation into cancer and nutrition. 1Urothelial cell carcinomas (UCC): morphology codes 812 and 813, behavior coded as 
carcinoma in situ and malignant. 2The category aggressive UCC includes T1 or higher, all CIS and all WHO 1973 Grade 3 carcinomas (including Ta Grade 3). 
3The category non-aggressive UCC includes Ta Grade 1 and Ta Grade 2 carcinomas.  
Table 2. Baseline characteristics of the participants in the EPIC cohort according to levels of alcohol consumption  
 Alcohol consumption (grams/day) 
Females 0 >0-3  >3-12 >12-24 >24-60 > 60 
Number of participants (n) 54,735 106,742 99,824 44,161 26,280 2,177 
Mean age at baseline (years) 52.3 50.2 50.4 51.0 51.7 51.8 
University degree or higher (%) 12.9 20.4 27.4 30.6 31.8 37.7 
Never smokers (%) 67.3 59.5 55.6 52.1 42.3 33.6 
Body mass index (Kg/m2) 26.5 25.1 24.5 24.2 24.2 24.6 
Moderately active / active (%) 32.0 44.7 47.1 44.2 43.7 42.3 
Energy intake (kcal/day) 1,835 1,844 1,941 2,073 2,180 2,483 
Males 0 >0-6 >6-12 >12-24 >24-60 > 60 
Number of participants (n) 9,199 35,904 23,929 29,265 34,580 9,364 
Mean age at baseline (years) 54.3 51.1 52.0 52.6 52.4 53.0 
University degree or higher (%) 15.1 24.1 30.0 31.9 29.1 22.6 
Never smokers (%) 34.6 43.7 38.4 31.8 25.2 16.4 
Body mass index (Kg/m2) 26.9 26.2 26.2 26.4 26.7 27.4 
Moderately active / active (%) 41.3 47.2 49.3 50.5 52.1 54.3 
Energy intake (kcal/day) 2,289 2,243 2,315 2,401 2,557 2,894 
 
EPIC: European prospective investigation into cancer and nutrition. Alcohol consumption was significantly associated with all characteristics (P<0.001) 






HR (95% CI) 
Males 
HR (95% CI) 
Females 
HR (95% CI) 
Never smokers 
HR (95% CI) 
Smokers 
HR (95% CI) 
Alcohol overall 476,160 1.03 (1.00-1.06) 1.02 (0.99-1.06) 1.05 (0.96-1.14) 0.93 (0.84-1.03) 1.04 (1.01-1.07) 
Beer 476,160 1.02 (0.96-1.07) 1.02 (0.96-1.07) 0.97 (0.73-1.30) 0.91 (0.73-1.14) 1.03 (0.97-1.08) 
Wine 476,160 1.02 (0.98-1.07) 1.02 (0.97-1.06) 1.05 (0.94-1.17) 0.93 (0.80-1.09) 1.04 (0.99-1.09) 
Spirits  476,160 1.07 (0.99-1.15) 1.06 (0.97-1.15) 1.09 (0.89-1.34) 1.08 (0.77-1.51) 1.07 (0.99-1.16) 





HR (95% CI) 
Males 
HR (95% CI) 
Females 
HR (95% CI) 
Never smokers 
HR (95% CI) 
Smokers 
HR (95% CI) 
Alcohol overall 363,309 1.02 (0.99-1.05) 1.02 (0.99-1.05) 0.98 (0.85-1.14) 0.93 (0.81-1.06) 1.02 (0.99-1.05) 
Beer 363,309 0.98 (0.91-1.05) 0.98 (0.90-1.05) 0.83 (0.44-1.53) 0.73 (0.50-1.08) 0.98 (0.91-1.05) 
Wine 363,309 1.02 (0.97-1.07) 1.02 (0.97-1.07) 1.01 (0.82-1.25) 1.01 (0.83-1.22) 1.03 (0.98-1.08) 
Spirits  363,309 1.04 (0.98-1.09) 1.04 (0.98-1.09) 0.99 (0.70-1.41) 0.94 (0.65-1.34) 1.04 (0.99-1.11) 
 
UCC: urothelial cell carcinomas; HR: hazard ratio; CI: confidence interval. All models were stratified by age, gender and study center and adjusted for 
smoking status, energy intake, body mass index, physical activity and educational level completed  
Table 4. Association between categories of alcohol consumption and the risk of UCC by gender and by smoking status  
Alcohol consumption  
at baseline (grams/day) 
All Males Females Never smokers Smokers 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
Non-drinker 191 1.04 (0.87-1.25) 84 0.88 (0.69-1.14) 107 1.27 (0.97-1.66) 57 0.95 (0.67-1.35) 134 1.09 (0.88-1.36) 
>0-6(M)/>0-3(F) 443 Reference 298 Reference 145 Reference 121 Reference 317 Reference 
>6-12(M)/>3-12(F) 343 1.00 (0.86-1.15) 199 0.98 (0.82-1.18) 144 1.02 (0.80-1.30) 79 0.89 (0.67-1.20) 261 1.03 (0.87-1.22) 
>12-24 352 1.11 (0.95-1.28) 276 1.09 (0.92-1.29) 76 1.08 (0.81-1.45) 60 1.08 (0.78-1.51) 289 1.12 (0.95-1.33) 
>24-60 371 1.07 (0.92-1.25) 318 1.02 (0.86-1.21) 53 1.19 (0.85-1.65) 37 0.84 (0.56-1.26) 332 1.12 (0.94-1.33) 
>60-96(M)/>60(F) 76 1.04 (0.80-1.36) 72 0.99 (0.75-1.31) 4 1.16 (0.42-3.19) 4 0.72 (0.25-2.02) 72 1.11 (0.84-1.46) 




All Males Females Never smokers Smokers 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
UCC 
cases 
HR (95% CI) 
Non-drinker 43 0.89 (0.63-1.26) 10 0.75 (0.39-1.45) 33 0.94 (0.62-1.42) 27 1.14 (0.70-1.85) 16 0.70 (0.42-1.20) 
>0-6(M)/>0-3(F) 259 Reference 142 Reference 117 Reference 85 Reference 172 Reference 
>6-12(M)/>3-12(F) 282 0.94 (0.79-1.12) 146 0.99 (0.78-1.26) 136 0.89 (0.69-1.15) 75 0.98 (0.71-1.36) 206 0.93 (0.76-1.15) 
>12-24 284 1.05 (0.88-1.29) 230 1.08 (0.87-1.34) 54 0.94 (0.67-1.32) 47 1.15 (0.78-1.69) 237 1.04 (0.85-1.28) 
>24-60 282 1.01 (0.83-1.22) 260 0.98 (0.79-1.23) 22 1.34 (0.83-2.15) 25 0.92 (0.56-1.52) 257 1.02 (0.82-1.26) 
>60-96(M)/>60(F) 64 1.09 (0.81-1.49) 64 1.10 (0.80-1.52) 0 - 3 0.82 (0.24-2.81) 61 1.10 (0.80-1.53) 
>96(M) 34 1.35 (0.91-2.00) 34 1.32 (0.88-2.00) - - 0 - 34 1.36 (0.90-2.05) 
 
UCC: urothelial cell carcinomas; HR: hazard ratio; CI: confidence interval: M: males; F: females. All models were stratified by age, gender and study center and 
adjusted for smoking status, energy intake, body mass index, physical activity and educational level completed  
